Keya Medical Technology Co., Ltd. (Keya Medical), a leader in medical AI technology development, announced that it has completed a $30 Million Series C funding round led by IDG Capital, with participation from investors Alwin Capital, Source Code Capital, and Tasly Group.
This investment is the third large-scale funding round that Keya Medical has completed in just nine months. In February, Keya Medical received a strategic investment led by Kunlun Internet Smart Fund, and a joint co-investment by Growth FOF, and Alwin Capital. In August, Keya Medical was awarded an additional $22 million in a Series B+ funding round.
Despite the impact of the COVID-19 pandemic, Keya Medical has continued to accelerate progress in medical AI. The company’s flagship product, DEEPVESSEL FFR, became the first AI software medical device to receive National Medical Products Administration approval in January, and is the only CT-derived FFR product approved for clinical use in China. Keya Medical has adhered to the product development principle of developing solutions that are based on “real clinical needs,” using funds to bring products to market that empower both clinicians and patients.
Keya Medical will use this investment to support the global commercial development of Keya Medical’s products, providing an important driving force for subsequent product development and market expansion. Keya Medical welcomes collaboration partners around the world to help support progress.
Founded in Boston in 1992, IDG Capital is an investment and asset management firm that specializes in venture capital, private equity, and mergers & acquisitions. The firm currently has offices in fifteen cities around the world, including New York, Boston, London, Beijing, Shanghai, Hong Kong, Seoul and Hanoi.